LARGE Expression Augments the Glycosylation of Glycoproteins in Addition to α-Dystroglycan Conferring Laminin Binding by Zhang, Zhen et al.
LARGE Expression Augments the Glycosylation of





Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York, United States of America
Abstract
Mutations in genes encoding glycosyltransferases (and presumed glycosyltransferases) that affect glycosylation and
extracellular matrix binding activity of a-dystroglycan (a-DG) cause congenital muscular dystrophies (CMDs) with central
nervous system manifestations. Among the identified genes, LARGE is of particular interest because its overexpression
rescues glycosylation defects of a-DG in mutations of not only LARGE but also other CMD-causing genes and restores
laminin binding activity of a-DG. It is not known whether LARGE protein glycosylates other proteins in addition to a-DG. In
this study, we overexpressed LARGE in DG-deficient cells and analyzed glycosylated proteins by Western blot analysis.
Surprisingly, overexpression of LARGE in a-DG-deficient cells led to glycosylation dependent IIH6C4 and VIA4-1
immunoreactivity, despite the prevailing view that these antibodies only recognize glycosylated a-DG. Furthermore, the
hyperglycosylated proteins in LARGE-overexpressing cells demonstrated the functional capacity to bind the extracellular
matrix molecule laminin and promote laminin assembly at the cell surface, an effect that was blocked by IIH6C4 antibodies.
These results indicate that overexpression of LARGE catalyzes the glycosylation of at least one other glycoprotein in addition
to a-DG, and that this glycosylation(s) promotes laminin binding activity.
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Introduction
Congenital muscular dystrophies (CMDs) with central nervous
system and eye malformations such as Walker-Warburg Syndrome
(WWS), Muscle-eye-brain disease (MEB), Fukuyama congenital
muscular dystrophy (FCMD), and Congenital muscular dystrophy
type 1D (MDC1D) can be caused by mutations in genes encoding
glycosyltransferases (or putative glycosyltransferases). Some of
these genes, which include POMT1 [1,2]; POMT2 [3]; POMGnT1
[4]; LARGE [5]; FKTN [6,7]; and FKRP [8,9], are involved in the
synthesis of O-linked mannosyl glycans, such as, Siaa2,3-
Galb1,4GlcNAcb1,2Man-Ser/Thr and Galb1,4(Fuca1,3)Glc-
NAcb1,2Man-Ser/Thr [10–12]. Protein O-mannosyltransferase
1 and 2 (POMT1 and 2) form a mutually indispensible enzyme
complex and catalyze the first step in the O-mannosyl glycosyl-
ation pathway, transferring mannose to serine or threonine
residues [13,14]. Protein O-mannose N-acetylglucosaminyltrans-
ferase 1 (POMGnT1) transfers N-acetylglucosamine to O-linked
mannose forming a b1,2 linkage [4,15]. Enzymes that catalyze
further extension of O-mannosyl glycans have not been identified.
In particular, the substrates of fukutin (encoded by FKTN), fukutin-
related protein (encoded by FKRP), and like-acetylglucosaminyl-
transferase (LARGE) are not yet fully elucidated. Studies indicate
that LARGE modifies O-linked mannosyl glycans, complex N-,
and mucin O-glycans [16,17], and more recent data indicate that
LARGE is involved in extension of an unidentified phosphoryl
glycosylation branch on O-linked mannose [18].
O-linked mannosyl glycans account for 1/3 of O-linked glycans
in the brain [19–22]. The only known target of O-mannosyl
glycosylation is a-dystroglycan (a-DG), a widely expressed cell
surface glycoprotein that binds to the transmembrane b-DG
[23,24]. Together with b-DG (encoded by the same gene as a-DG,
Dag1), it links the extracellular matrix (ECM) and cytoskeleton
[24,25] in that a-DG binds with high affinity to several
extracellular matrix components, including laminin [26–30], agrin
[31,32], perlecan [33,34], neurexin [35], and pikachurin [36],
while b-DG interacts with cytoskeletal elements. Glycosylation
mediates a-DG interaction with the extracellular matrix based on
studies using monoclonal antibodies IIH6C4 and VIA4-1 that
recognize glycosylated epitopes of a-DG [24,27]. Specifically,
hypoglycosylation leads to the loss of immunoreactivity to IIH6C4
(and VIA4-1) [37–40]. Moreover, hypoglycosylation of a-DG
resulting from mutations in POMT1, POMT2, and POMGnT1, as
well as mutations in LARGE, FKTN, and FKRP significantly reduces
laminin binding activity [37–42].
LARGE is one of the largest genes in the human genome with
two putative glycosyltransferase domains [43]. Large
myd mice bear
an intragenic deletion in the Large gene [41], and exhibit neuronal
migration defects in the brain and eye abnormalities similar to
CMDs in humans [44]. LARGE interacts with the N-terminal
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domains abolish glycosylation activity, suggesting that LARGE
functions as a glycosyltransferase [17]. Overexpression of LARGE
leads to hyperglycosylated a-DG in that IIH6C4 immunoreactiv-
ity migrates at a higher apparent molecular mass on SDS-PAGE,
compared to wildtype [46]. Interestingly, LARGE overexpression
results in restoration of laminin binding activity in cells isolated
from not only Large
myd mice, but also patients with WWS, MEB,
and FCMD. The ability to hyperglycosylate a-DG and ‘‘rescue’’
its laminin binding activity is unique to LARGE and its homolog
LARGE2 [46–48]. These studies raise the hope of using LARGE
in gene therapy for all congenital muscular dystrophies caused by
defective a-DG glycosylation.
In this study, we examined whether LARGE could regulate the
glycosylation of glycoproteins other than DG. Overexpression of
LARGE was studied in DG-deficient neural stem cells using
immunobloting with IIH6C4 and VIA4-1 antibodies in conjunc-
tion with a laminin binding assay. Our results show that LARGE
glycosylates at least one glycoprotein in addition to a-DG that
confers laminin binding activity.
Materials and Methods
Ethics statement
Protocols for animal usage were approved by the Institutional
Animal Care and Use Committee of Upstate Medical University
(Permit Number: 066) and adhered to National Institutes of
Health guidelines. All surgery was performed under anesthesia
with sodium pentobarbital. All efforts were made to minimize
suffering.
Antibodies
Antibodies were obtained as follows: Anti-a-DG antibodies
IIH6C4 and VIA4-1 [27] from Millipore Corporation (Billerica,
MA); Anti-b-DG (MANDAG2-7D11) from Developmental Stud-
ies Hybridoma Bank (University of Iowa, Department of Biology);
Rabbit polyclonal antibodies against laminin-1 and c-Myc from
Sigma-Aldrich (St. Louis, MO); Anti-b-DG (43DAG1/8D5) from
Abcam (Cambridge, MA); b1 integrin blocking antibody [49] from
Biolegend (San Diego, CA).
Neural stem cell culture
To obtain brain-specific DG-deficient neural stem cells, Dag1-
floxed mice [50] were crossed with Nestin-Cre transgenic mice
[51] (both from the Jackson Laboratories, Bar Harbor, ME).
Genotyping of Dag1-floxed allele and Nestin-Cre transgene was
carried out by polymerase chain reaction (PCR). For Nestin-Cre,
primers were recommended by the Jackson Laboratories. For
Dag1-floxed allele, the wildtype primers were GGGAGAG-
GACTCGAACACTG and GTCTGGGGAGAAGGAAGGTC,
whereas the floxed primers were TGAATGAACTGCAGGAC-
GAG and ATACTTTCTCGGCAGGAGCA. The predicted
amplicons for wildtype and floxed alleles were 243 bp, and
160 bp, respectively.
Primary neural stem cell cultures were isolated from embryonic
day (E) 13.5 fetal brains (noon on the date of plug observation was
considered E 0.5) of wildtype and knockout (Dag1
f/f;Nestin-Cre+)
fetuses. The neocortical wall was excised, trypsinized, and
triturated. The dissociated cells were cultured as neural spheres
in neural basal medium (Invitrogen, Carlsbad, CA) supplemented
with B27 (minus vitamin A), 20 ng/ml FGF-2, 20 ng/ml EGF,
and 2 ng/ml heparin.
To obtain clones of DG knockout neural stem cells, the neural
spheres were trypsinized and triturated into individual cells. Ten
ml of diluted cells (at a concentration of 6 cells/ml) were seeded
in a 100 mm615 mm fibronectin-coated tissue culture dish.
Fresh FGF-2, EGF, and heparin were added once every three
days. The individual colonies were picked with a pipettor and
subcultured in a 12-well plate with 1 ml culture medium for a
week. The cloned neural stem cells were expanded as neural
spheres. Genomic DNA was then extracted from each clone and
genotyped by PCR to identify Dag1 null locus (Dag1 locus with
sequences flanked by loxP sites deleted by Cre) with the
following primers: GGCCTTCCTCTTGACACTGA and
GGACAGTCACTGGCTCATCA. The expected PCR frag-
ment for the wildtype was a 217 bp amplicon. The Dag1 null
locus does not generate a fragment. Dag1 null locus was
confirmed by a pair of mutant primers CGAACACTGAGTT-
CATCC and CAACTGCTGCATCTCTAC [46]. The predict-
ed ampicon for the mutant allele was 585 bp. The wildtype locus
does not generate a fragment. Detection of immunoreactivity to
IIH6C4 and VIA4-1, laminin overlay, and antibody blocking
experiments on DG knockout cells were repeated in at least two
independent clones.
RT-PCR with primers GCTCATTTCGAGTGAGCATTCC
and CTAGTTTCCAGGACAGGAGA was used to determine
the expression of dystroglycan mRNA [46]. These primers anneal
to exon 3 and exon 4 of Dag1 locus and produce a 561 bp
amplicon when dystroglycan mRNA is expressed. Dystroglycan
knockout neural stem cells were not expected to generate a
fragment. RT-PCR for 18S rRNA was used as a normalization
control [52]. Dag1 null neural stem clones were further evaluated
by Western blot analysis with anti-b-DG antibody and immuno-
fluorescence staining with a b-DG antibody. Anti-b-DG immu-
noreactivity was undetectable in Dagl null clones, whereas a
protein of apparent molecular mass of 43 kDa was detected in
wildtype cells.
Western blot and Laminin overlay experiments
Cultured neural spheres were pooled by centrifugation and
disrupted using a Dounce homogenizer and cold lysis buffer
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% TritonX-100)
supplemented with a protease inhibitor cocktail (Roche Diagnos-
tics, Indianapolis, IN) then centrifuged at 16,100 g for 20 min at
4uC. The supernatants were collected, and 50 ml of wheat germ
agglutinin (WGA)-agarose (EY Laboratories, San Mateo, CA) was
added to 2 mg of total protein lysate. After incubation for 4 hrs,
the WGA-gel was centrifuged and washed 3 times with the lysis
buffer. Bound glycoproteins were eluted by SDS-PAGE loading
dye, separated on SDS-PAGE, and electrotransferred onto
polyvinylidene fluoride (PVDF) membranes.
For immunoblotting analysis with IIH6C4, MANDAG2-7D11,
and anti-c-Myc antibodies, PVDF membranes were blocked with
3% BSA in TBST (50 mM Tris, pH 7.4, 150 mM NaCl, 0.05%
Tween-20) for 30 min and incubated with primary antibodies in
TBST and 3% BSA for two hrs. After washing with TBST, the
membranes were incubated with goat anti-mouse IgG (or IgM) or
rabbit IgG conjugated with horseradish peroxidase (1:3000) for
45 min. After extensive washing with TBST, the signal was
visualized with SuperSignal west pico chemiluminescent substrate
(Thermo Scientific).
For immunoblotting analysis with VIA4-1, after primary
antibody incubation and washing, the PVDF membrane was
incubated with biotinylated goat anti-mouse IgG and washed. The
membrane was then incubated with peroxidase-conjugated
streptavidin, and the signal visualized as above.
For immunoprecipitation with VIA4-1 antibody, 1.5 mg of total
lysate protein was used. Affinity purified VIA4-1 was mixed with
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G beads (Thermo Scientific, Rockford, IL) were added and rotated
overnight. Beads were washed 3 times with washing buffer
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1% Triton X-
100) at 4uC. The immunoprecipitated proteins were then eluted
with 5X SDS-PAGE loading dye, boiled for 5 minutes, separated
by 8% gel, and electrotransferred onto PVDF membranes.
For the laminin-overlay assay, PVDF membranes were
incubated with Tris-buffered saline (TBS, 50 mM Tris, pH 7.4,
150 mM NaCl) containing 3% BSA, 1 mM CaCl2, and 1 mM
MgCl2 for one hr to block nonspecific binding. The membranes
were then incubated with 1.25 mg/ml laminin-1 (Invitrogen) in
TBST containing 1 mM CaCl2 and 1 mM MgCl2 overnight at
4uC. After extensive washing, bound laminin was detected by
standard Western blot procedures as above except that all buffers
contained 1 mM CaCl2 and 1 mM MgCl2.
Adenoviral overexpression of LARGE
An adenoviral vector for overexpression of myc-tagged human
LARGE (Ad-LARGE) was constructed at Vector Biolabs (Phila-
delphia, PA). Following the coding region of LARGE, a DNA
segment containing internal ribosome entry site-enhanced green
fluorescent protein (IRES-eGFP) sequence was inserted to co-
express eGFP as a reporter. Neural stem cells were cultured in
150 mm620 mm dishes. The Ad-LARGE virus (20 mlo f5 610
12
viral particles/ml) was added to the culture medium when the cells
were 50%–70% confluent. Two days after infection, cells were
harvested for Western blot analyses.
Removal of N-glycans
Peptide N-glycosidase F (PNGase F) (New England Biolabs,
Inc., Ipswich, MA) treatment to remove N-glycans of glycoproteins
in VIA4-1 immunoprecipitates was carried out according to
Figure 1. Establishment of dystroglycan-deficient neural stem cells. Primary neural stem cells isolated from brain specific knockout fetuses
of dystroglycan were clonally expanded, and genotyping performed with knockout specific primers specifying intron 3. Western blot with b-DG
antibody, and immunoflurescence staining with b-DG antibody were carried out to confirm successful knockout in clones. (A) Genotyping. (B) RT-PCR.
(C) Western blot with b-DG antibody. (D and E) Anti-b-DG immunofluorescence staining of wildtype and knockout neural stem cells respectively.
Abbreviations: DG, dystroglycan; DGKO, dystroglycan knockout. Scale bar in E: 50 mm.
doi:10.1371/journal.pone.0019080.g001
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glycoprotein denature buffer by incubating at 95uC for 10 min.
After quick chilling on ice, reaction buffer containing proteinase
inhibitor cocktail (Roche) was added. PNGase F (50 units) was
then added to the mixture and incubated at 37uC for 16 hrs. As a
control, heat inactivated PNGase F was added to the control
samples and incubated likewise.
Laminin binding on neural stem cells and semi-
quantitative analysis
Neural stem cells were grown on 8-well chamber slides coated
with fibronectin. Two days after infecting with the Ad-LARGE
virus, Laminin-1 (Invitrogen) was added to the culture medium
and incubated for 1, 6, and 12 hrs. For IIH6C4 antibody blocking
experiment, the antibody was diluted 20-fold in culture medium,
and cells were incubated for 2 hrs before exposure to laminin for
6 hrs. Cells were then washed 3 times with culture medium and
fixed with 4% paraformaldehyde for 15 min. Bound laminin was
detected by immunofluorescence staining with anti-laminin-1
antibody. Primary and secondary antibody incubations were
performed as described previously [53,54] and counterstained for
10 min with 0.10% 49,6-diamidino-2-phenylindole (DAPI) (Sig-
ma-Aldrich). Fluorescence was visualized with a Zeiss Axioskop
upright fluorescence microscope equipped with a digital camera
with 40X objective (Carl Zeiss Microimaging, Inc., Thornwood,
NY).
To quantify bound laminin, digital immunofluorescence images
were taken in quadruplicate at the same exposure condition such
that the brightest spot was below saturation. The images were
analyzed with ImageJ Software (NIH, ImageJ 1.41) such that the
Figure 2. LARGE can hyperglycosylate glycoprotein(s) in DG-deficient neural stem cells that bind to laminin. Clonally expanded Dag1
null neural stem cells were infected with the Ad-LARGE virus. WGA-enriched glycoproteins were then isolated from total cell lysates, separated on
SDS-PAGE, and blotted onto PVDF membranes. Laminin overlay, immunoblot with IIH6C4, VIA4-1, and anti-b-DG were then carried out. Note that
IIH6C4 and VIA4-1 immunoreactivity and laminin binding was not detectable in DG-deficient cells but was detectable in DG-deficient neural stem
cells with LARGE overexpression. The 225 kDa band in laminin overlay assays were from endogenously expressed laminin (not the exogenous
laminin). Abbreviations: DG, dystroglycan; DGKO, DG knockout; kDa, kilo Dalton; WGA, wheat germ agglutinin; WT, wildtype.
doi:10.1371/journal.pone.0019080.g002
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in the area of interest) was measured. The integrated density of the
images from cells without laminin treatment was considered 0 and
used to establish the threshold for subtraction of background
fluorescence in other images. For each time point, the mean and
its standard error were then calculated. Cell numbers on the
images were counted manually from DAPI fluorescence. To
analyze individual laminin aggregates, the numbers and integrated
density were determined by using the ‘‘Analyze Particles’’
function. To analyze filament-shaped versus dot-shaped aggre-
gates, an aggregate with ‘‘Circularity’’ (4p6Area/Perimetre
2)o f0
to 0.7 was considered a filament-shaped aggregate while an
aggregate with ‘‘Circularity’’ of 0.7 to 1 was considered dot
shaped.
Results
Isolation and characterization of dystroglycan knockout
neural stem cells
To obtain brain-specific knockout of a-DG, Dag1-floxed mice
were crossed with Nestin-Cre transgenic mice to produce
Dag1
f/f;Nestin-Cre+. These mice showed similar central nervous
system phenotypes as GFAP-Cre-mediated knockout of DG [50].
Neural specific deletion of DG would not affect DG expression in
non-neural cells such as blood vessels. Therefore, to obtain DG-
null cells for biochemical analysis, we isolated neural stem cells
from Dag1
f/f;Nestin-Cre+ fetuses at E13.5, and verified that these
cells were immunoreactive to the neural stem cell marker RC2.
To ensure that the cells were DG deficient, cell cultures were
clonally expanded, and ten clones were isolated and genotyped by
PCR. As expected, these expressed a 585 bp ampicon specifying
the mutant clones (DGKO-3, DGKO-12, and DGKO-15 as
examples), while the wildtype neural stem cells expressed the
217 bp amplicon (Figure 1A). Loss of dystroglycan gene
expression was confirmed by RT-PCR (Figure 1B). Consistent
with this, b-DG immunoreactivity was undetectable in the
knockout clones, while the wildtype clones expressed a 43 kDa
protein on Western blot (Figure 1C) and immunocytochemistry
(Figures 1D, E). Moreover, cells rendered null for a-a n db-DG
did not show noticeable changes in cellular morphology or
growth rate as compared with the wildtype cells. Altogether, these
results indicate that the putative knockout clones were dystrogly-
can nulls showing no detectable expression of DG mRNA or
protein.
Overexpression of LARGE in DG-deficient neural stem
cells caused hyperglycosylation of non-a-DG targets
To examine whether there are non-a-DG targets for LARGE-
mediated glycosylation, we infected DG-deficient neural stem cell
clones with the Ad-LARGE virus. Two days later, WGA-
enriched glycoproteins were isolated from cell lysates and
analyzed with IIH6C4 antibody, laminin overlay, and anti-b-
DG Western blot. In control neural stem cells that were Cre-
negative (considered as wildtype, WT), IIH6C4 immunoreactivity
was detected at about 120 kDa (Figure 2A). IIH6C4 immuno-
reactive a-DG bound to laminin in the laminin overlay assay.
Overexpression of LARGE in the controls (WT + Ad-LARGE)
increased the amount of IIH6C4 immunoreactivity, and the
apparent molecular mass of immunoreactive proteins. IIH6C4
immunoreactive species in LARGE-overexpressing wildtype cells
migrated as a smear. Laminin overlay indicated laminin binding
activity was increased by LARGE overexpression in wildtype
cultures. As expected, b-DG was detected in the WGA-enriched
glycoproteins from wildtype cells, and wildtype cells overexpress-
ing LARGE.
In DG-deficient neural stem cells (DGKO), IIH6C4 immuno-
reactivity and laminin binding activity were not detected at
,120 kDa, indicating the absence of a-DG (Figure 2A). Also as
expected, b-DG immunoreactivity was undetectable, indicating
that the cells were deficient in total DG. These results were
expected because IIH6C4 is thought to recognize a carbohydrate
epitope on a-DG. Unexpectedly, strong IIH6C4 immunoreactivity
was detected in the DG-deficient neural stem cells overexpressing
LARGE (DGKO + Ad-LARGE). The IIH6C4 immunoreactive
species did not belong to recombinant LARGE since the Myc-
tagged LARGE migrated at ,100 kDa (Figure 2, both panels).
In addition, LARGE overexpression in DG-deficient cells restored
laminin binding. In DG-deficient cells overexpressing LARGE,
the IIH6C4 immunoreactive and laminin-binding protein species
migrated at a higher molecular weight than wildtype cells
overexpressing LARGE (compare lanes WT + Ad-LARGE with
DGKO + Ad-LARGE). The laminin overlay experiment also
detected a 225 kDa protein of endogenous laminin expressed by
DG-deficient cells as well as wildtype cells. As a control, b-DG was
not detected in DG-deficient cells with or without LARGE
overexpression. Anti-c-Myc specifically detected Myc-tagged
LARGE in cells treated with the Ad-LARGE virus. There was
no apparent difference in expression of LARGE in wildtype and
knockout cells. These results indicate that there are non-a-DG
Figure 3. Hyperglycosylated proteins in DG deficient neural
stem cells were also recognized by VIA4-1 and some were
sensitive to peptide N-glycosidase F. Lysates of DG-deficient
neural stem cells with or without LARGE overexpression were
immunoprecipitated with VIA4-1 antibody. (A) The immunoprecipitates
were analyzed by immunoblotting with IIH6C4. (B) The VIA4-1
immunoprecipitates were treated with PNGase F and analyzed by
immunoblotting with IIH6C4. Abbreviation: DGKO, dystroglycn knock-
out; IP, immunoprecipitation.
doi:10.1371/journal.pone.0019080.g003
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glycoprotein fractions.
Similar results were obtained using the VIA4-1 antibody. VIA4-
1 immunoreactivity was observed at 120 kDa in lysates from
wildtype cells (arrow in Figure 2A). The use of biotin-avidin
amplification technique in VIA4-1 immunoblot produced a
nonspecific band migrating at 125 kDa. LARGE overexpression
caused a dramatic increase in VIA4-1 immunoreactivity similar to
IIH6C4 immunoreactivity (Figure 2A). In dystroglycan-deficient
neural stem cells, VIA4-1 immunoreactivity was not detectable.
However, LARGE overexpression produced VIA4-1 immunore-
active species at high molecular weight range as well (Figure 2A).
In addition, we used VIA4-1 antibody to immunoprecipi-
tate proteins from lysates of LARGE-overexpressing DG-
deficient cells. The immunoprecipitate from LARGE overex-
pressing DG-deficient cells showed strong immunoreactivity to
IIH6C4 and bound to laminin in the laminin overlay assay
(Figure 3A). IIH6C4 antibody did not work in the immuno-
precipitation assay. These results indicate that a substrate (s)
other than a-DG is hyperglycosylated when LARGE is
overexpressed, which is recognized by IIH6C4 and VIA4-1
and binds to laminin.
In wildtype cells, IIH6C4 immunoreactivity and laminin binding
could not be detected from total lysate (Figure 2B). However,
Figure 4. Overexpression of LARGE increased IIH6C4 immunoreactivity on DG-deficient neural stem cells. Neural stem cells were
cultured on fibronectin-coated chamber slides and infected with the Ad-EGFP (A–D) and Ad-LARGE viruses (E–H). Two days later, cells were fixed and
immunostained with IIH6C4 antibody. (A, C, E, and G) Wildtype neural stem cells. (B, D, F, and H) DG-deficient neural stem cells. Note that LARGE
overexpression increased IIH6C4 immunoreactivity in both the wildtype and DG-deficient neural stem cells (compare E and F to A and B).
Abbreviations: DGKO, DG knockout; WT, wildtype. Scale bar in H: 50 mm.
doi:10.1371/journal.pone.0019080.g004
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observed in total lysate of wildtype cells with overexpression of
LARGE (WT + Ad-LARGE). Similarly, IIH6C4 and VIA4-1
immunoreactivityand lamininbinding werealsoseen intotallysates
ofDG-deficientcellsafteroverexpression ofLARGE(DGKO+ Ad-
LARGE). As expected, b-DG was not detected in total lysates of
DG-deficient cells with or without LARGE overexpression.
Peptide N-glycosidase F treatment only slightly reduced
IIH6C4 immunoreactivity
A significant amount of IIH6C4 immunoreactivity in LARGE
overexpressing Chinese hamster ovary cells were N-linked
because they were sensitive to PNGase F treatment [16]. To
determine whether LARGE overexpression modified N-glycans
of non-a-DG glycoproteins, we treated VIA4-1 immunoprecip-
itated proteins from LARGE overexpressing DG-deficient cells
with PNGase F and immunoblotted with IIH6C4 (Figure 3B).
There was a modest reduction in IIH6C4 immunoreactivity upon
PNGase F treatment. When IIH6C4 immunoreactivity from 3
independent experiments was quantified by densitometric
analysis, it revealed that PNGase F reduced IIH6C4 immuno-
reactivity by 16.3% (95% confidence interval: 24.9% to 2.9%).
These results indicate that LARGE can modify N-glycans on
some non-a-DG glycoproteins.
Figure 5. Overexpression of LARGE increased VIA4-1 immunoreactivity on DG-deficient neural stem cells. Neural stem cells were
cultured on fibronectin-coated chamber slides and infected with the Ad-EGFP (A–D) and Ad-LARGE viruses (E–H). Two days later, cells were fixed and
immunostained with VIA4-1 antibody. (A, C, E, and G) Wildtype neural stem cells. (B, D, F, and H) DG-deficient neural stem cells. Note that LARGE
overexpression increased VIA4-1 immunoreactivity in both the wildtype and DG-deficient neural stem cells (compare E and F to A and B).
Abbreviations: DGKO, DG knockout; WT, wildtype. Scale bar in H: 50 mm.
doi:10.1371/journal.pone.0019080.g005
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located on the plasma membrane
To determine whether LARGE overexpression increased
IIH6C4 immunoreactivity on the cells, we carried out immuno-
fluorescence staining of neural stem cells that were infected with
the Ad-LARGE virus. In wildtype cells, IIH6C4 immunofluores-
cence was readily observed (Figure 4A). Overexpression of
LARGE increased the intensities of IIH6C4 immunofluorescence
(Figure 4E). In DG-deficient cells, IIH6C4 immunofluorescence
was barely detected (Figure 4B). However, overexpression of
LARGE increased IIH6C4 immunofluorescence in these cells
(Figure 4F). When cells were examined by indirect immunoflu-
orescence with the VIA4-1 antibody, similar results were obtained
(Figure 5) in that LARGE overexpression increased immunoflu-
orescence intensities both in the wildtype cells and DG-deficient
cells (compare Figure 5E with A and F with B). The staining
pattern with VIA4-1, however, was slightly different from that of
IIH6C4. VIA4-1 immunofluorescence showed a more punctate
pattern with cellular processes rarely stained.
LARGE overexpression in DG-deficient cells promoted
laminin binding at the cell surface
Functionally glycosylated a-DG is not only recognized by
IIH6C4 antibody but also binds to extracellular matrix
Figure 6. Overexpression of LARGE in DG-deficient neural stem cells promoted laminin binding at the cell surface. Neural stem cells
were cultured on fibronectin-coated chamber slides and infected with Ad-EGFP (A–D) and Ad-LARGE viruses (E–H). Two days after infection, laminin
was added to the medium. The cells were washed and fixed 12 hrs later and immunostained with an antibody against laminin (red fluorescence, A, B,
E, and F). (A, C, E, and G) Wildtype neural stem cells. (B, D, F, and H) DG-deficient neural stem cells. Abbreviations: DGKO, DG knockout; WT, wildtype.
Scale bar in H: 50 mm (25 mm for inserts in A, B, E, and F).
doi:10.1371/journal.pone.0019080.g006
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glycoproteins hyperglycosylated by LARGE overexpression
promote laminin assembly at the cell surface, we added laminin
to the cell culture medium and assayed for bound laminin
by immunofluorescence staining. In the absence of LARGE
overexpression, laminin binding was detected on wildtype
neural stem cells (Figure 6A). LARGE overexpression aug-
mented the amount of laminin binding as revealed by overall
increase in anti-laminin immunofluorescence (Figure 6E). To
quantify the effect of LARGE overexpression, we measured
fluorescence intensities and found that overexpression of
LARGE in wildtype cells dramatically increased the overall
immunofluorescence intensities of bound laminin after 1 hr,
6 hrs, and 12 hrs of laminin incubation (Figure 7A, p,0.001,
Student’s t-test).
DG-deficient neural stem cells showed detectable but
markedly reduced amounts of bound laminin when compared
to the wildtype indicated by much weaker immunofluorescence
(compare Figure 6B with A). The residual laminin binding was
likely due to the presence of other laminin receptors such as
integrins. Overexpression of LARGE in DG-deficient neural
stem cells also increased binding of added laminin (compare
Figure 6F with B). When fluorescence intensities were
measured, the laminin immunofluorescence in DG-deficient
cells was dramatically decreased from the wildtype at all three
time points. However, LARGE overexpression markedly in-
creased laminin immunofluorescence intensities after 6 hrs and
12 hrs indicating increased laminin binding (Figure 7A,
p,0.01, Student’s t-test). Although laminin binding in DG-
deficient cells with LARGE overexpression could reach levels
comparable to the wildtype neural stem cells (Figure 7A, 6 hrs
and 12 hrs), it did not reach the level of wildtype cells
overexpressing LARGE at any of the time points.
It appeared that LARGE overexpression increased the total
amount of bound laminin by boosting the amount of laminin per
aggregates as indicated by their larger sizes and stronger
fluorescence intensities. To quantify this effect, we first measured
the fluorescence intensities of the aggregates after 12 hrs of
incubation with laminin. The aggregates were grouped according
to their integrated fluorescence intensity (X-axis) in Figure 7B.
The percentage of aggregates with fluorescence intensity greater
than intensity indicated on the X-axis is shown on the Y-axis.
DG-deficient cells exhibited a leftward shift of the curve from the
wildtype, suggesting decreased average fluorescence intensity
from the wildtype. Overexpression of LARGE in both the
wildtype and DG-deficient cells shifted the curve to the right,
suggesting increased average fluorescence intensity compared to
cells without LARGE overexpression. We also measured the
areas occupied by the laminin aggregates with and without
LARGE overexpression which resulted in area measurements
similar to fluorescence intensity measurement. Overexpression of
LARGE increased the average area occupied by the laminin
aggregates in both the wildtype cells and DG-deficient cells (data
not shown).
Bound laminin aggregated into various sizes with two fre-
quent physical appearances: dot-shaped and filament-shaped
aggregates. Filament-shaped laminin aggregates were generally
much larger than dots with brighter overall fluorescence.
In the wildtype, 12.63% of aggregates were filamentous
(Figure 7C). Overexpression of LARGE increased the filamen-
tous aggregates to 29.91% (also compare Figure 6E with A,
Chi-square analysis, X
2=222.27, p,0.001). In DG-deficient
cells, LARGE overexpression increased filamentous aggregates
from 9.08% to 13.21% (also compare Figure 6F with B,C h i -
square analysis, X
2=21.88, p,0.001). Thus, similar to the
wildtype, bound laminin with filamentous morphologies were
more frequently observed in DG-deficient cells with LARGE
overexpression than without LARGE overexpression. In addi-
tion, the fluorescence intensities of filamentous aggregates were
markedly increased after overexpression of LARGE in both the
wildtype and DG knockout cells (Figure 7D). Taken together,
these data indicate that overexpression of LARGE in DG-
deficient neural stem cells increases laminin binding at the cell
surface, suggesting that non-a-DG targets of LARGE-mediated
glycosylation also mediate laminin binding upon overexpression
of LARGE.
Laminin binding by a-DG is blocked by the IIH6C4 antibody
[55]. To determine whether laminin binding activity by LARGE-
modified non-a-DG is sensitive to IIH6C4, a IIH6C4 blocking
experiment was performed. As expected, IIH6C4 pretreatment
inhibited laminin binding to wildtype neural stem cells with or
without LARGE overexpression (compare Figure 8A’ and E’
with A and E). While LARGE overexpression increased laminin
binding in dystroglycan-deficient cells, IIH6C4 pretreatment
significantly reduced laminin binding (compare Figure 8F’ with
F). As a control, an antibody that has been shown to block b1-
integrin function did not affect laminin binding in wildtype and
dystroglycan-deficient cells with or without LARGE overexpres-
sion (data not shown). Quantitative analysis of bound laminin
indicated that IIH6C4 inhibited laminin binding in LARGE-
overexpressing dystroglycan-deficient cells as well (Figure 8I).
IIH6C4 treatment reduced laminin binding in all cells (p,0.01
for all comparisons, Student t test). These results indicate that
laminin binding activity of non-a-DG proteins upon LARGE
overexpression is not only recognized by IIH6C4 but also can be
blocked by it.
Discussion
To date, DG is the only known substrate of the six
glycosyltransferases (or presumed glycosyltransferases) (POMT1,
POMT2, POMGnT1, LARGE, Fukutin, and FKRP) mutated in
CMDs. To determine if the presumed glycosyltransferase
LARGE recognizes other substrates, it was overexpressed in
DG-deficient neural stem cells. Western blot analysis revealed the
presence of IIH6C4 and VIA4-1 immunoreactive species in
WGA-enriched glycoproteins and in total lysates, supporting
glycosylation of a non-a-DG protein in neural stem cells
overexpressing LARGE. Moreover, laminin overlay analysis
demonstrated that this substrate(s) was capable of binding to
laminin, and LARGE overexpression promoted cell surface
binding of laminin in DG-deficient cells. Altogether, these results
Figure 7. Quantification of laminin binding on neural stem cells. (A) Comparison of overall laminin immunofluorescence intensities for
wildtype and DG-deficient neural stem cells with or without LARGE overexpression after incubating with laminin for 1, 6, and 12 hrs. (B) Distribution
of aggregate fluorescence intensities. Y-axis shows the percentage of laminin aggregates with fluorescence intensities greater than those shown on
the X-axis. (C) Quantification of filamentous and dot–shaped laminin aggregates. (D) Average fluorescence intensities of filamentous aggregates in
wildtype and DG-deficient cells with or without overexpression of LARGE. (E) Number of cells in the images analyzed for (A). Images from the 12 hour
data point were used for (B, C, and D). Abbreviations: DGKO, DG knockout; WT, wildtype.
doi:10.1371/journal.pone.0019080.g007
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PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e19080Figure 8. Laminin binding by non-a-DG glycoproteins in LARGE overexpressing DG-deficient cells was blocked by IIH6C4. IIH6C4
antibody was added to the culture medium of neural stem cells, laminin was added, and bound laminin was detected by immunofluorescence
staining. (A, C, E, and G) Wildtype neural stem cells. (B, D, F, and H) DG-deficient neural stem cells. (A’, C’, E’, and G’) Wildtype neural stem cells treated
with IIH6C4. (B’, D’, F’, and H’) DG-deficient neural stem cells treated with IIH6C4. (I) Quantification of bound laminin. Scale bar in H’: 50 mm.
doi:10.1371/journal.pone.0019080.g008
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glycoprotein(s) in addition to a-DG.
IIH6C4 and VIA4-1 epitopes are transferred to non-a-DG
upon LARGE overexpression
Immunoreactivity to two antibodies, IIH6C4 and VIA4-1, has
been widely used to evaluate functional glycosylation of a-DG on
unidentified carbohydrate epitopes [24,27]. Mutations in POMT1,
POMT2, and POMGnT1, LARGE, FKTN, and FKRP lead to
hypoglycosylation of a-DG and markedly reduce ligand binding
activity [37–42,56,57]. Interestingly, LARGE overexpression
produced IIH6C4 immunoreactive protein species that bind
laminin in cells isolated from both Large
myd mice and patients
with WWS, MEB, and FCMD [46]. It has been assumed that a-
DG is the only hyperglycosylated protein species that is produced
by LARGE overexpression [16,46–48,58]. Our results show that
overexpressing LARGE produces glycoproteins recognized by
IIH6C4 and VIA4-1 in DG-deficient cells. It is not known why
they were more immunoreactive to IIH6C4 than VIA4-1
(Figure 2). It is possible that LARGE-mediated modifications on
a-DG and proteins other than a-DG are not identical.
Nevertheless, these results indicate that non-a-DG species become
acceptors of LARGE-mediated glycosylation that are recognized
by IIH6C4 and VIA4-1.
LARGE as a glycosyltransferase
Several lines of evidence suggest that LARGE is a glycosyl-
transferase. First, it has two glycosyltransferase domains, one
similar to b-1,3-N-acetylglucosaminyltransferase and the other
similar to UDP-glucose:glycoprotein glucosyltransferase (UGGT)
[16,17,41]. Second, site-directed mutation of conserved DXD
motifs within the transferase domains abolishes LARGE’s ability
to generate IIH6C4 immunoreactivity by mislocalizing the mutant
protein to the endoplasmic reticulum [48] or by inactivating the
putative enzymatic domain [17]. Third, O-linked mannose can
have four different branches: (1) N-acetylglucosamine linked
through b1,2 linkage catalyzed by POMGnT1 [4], (2) N-
acetylglucosamine linked through b1,6 linkages catalyzed by
b1,6-N-acetylglucosaminyltransferase IX [59,60], (3) N-acetylglu-
cosamine linked through b-1,4, and (4) an unidentified phosphoryl
glycan linked to carbon-6 [18]. The extension of the phosphoryl
glycan branch requires the activity of LARGE [18]. Fourth,
overexpression of LARGE in CHO cells and some cancer cells
hyperglycosylate a-DG [16,17,58].
Prior to this work, the only known target of LARGE was a-DG
and three types of glycosylations were observed: N-linked, O-
linked mannosyl, and mucin type O-linked N-acetylgalactosamine
glycans. The present study shows that LARGE can modify non-a-
DG glycoproteins, and the modified non-a-DG species are
recognized by IIH6C4 and VIA4-1. Since previous studies have
generally used IIH6C4 and VIA4-1 immunoreactivity as evidence
of glycosylated a-DG after LARGE overexpression, it is likely that
IIH6C4-recognized species are heterogeneous, including non-a-
DG as well as a-DG. Future studies are needed to determine
whether LARGE hyperglycosylates one or more proteins other
than a-DG in other cells and if it mediates the same glycosylation
on other proteins as it does on a-DG.
In summary, this study shows that hyperglycosylation and
restoration of laminin binding by LARGE overexpression also
occurs in DG-deficient cells, indicating that proteins in addition to
a-DG are hyperglycosylated and capable of laminin binding. It is
not known whether these other targets represent one protein or
several proteins. Since diminished cell-extracellular matrix inter-
actions mediated by a-DG-laminin interaction underlie many
phenotypes found in congenital muscular dystrophies, restoring
cell-laminin interactions in congenital muscular dystrophies may
provide therapeutic benefit. Furthermore, recent evidence suggests
that silencing LARGE causes loss of laminin-a-DG binding in
epithelium-derived cancers [61]. LARGE forms a complex with
b3-N-acetylglucosaminyltransferase 1 (b3GnT1) and its glycosyl-
ation has tumor suppression activity [58]. Identifying the non-a-
DG glycoprotein(s) glycosylated by LARGE may provide novel
molecular targets for therapy.
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